N/A N=90 FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=42 Durability of Two Skin Barrier Protectants (SBP)
Skin Hydration in Healthy Volunteers
Primary: Duration — 36.71; 36.31; 7.95; 20.98 arbitrary units
N/A N=40 Effects of High-Intensity Interval Training Exercise in Adolescents With Hepatosteatosis
Non-Alcoholic Fatty Liver Disease · Insulin Resistance · High Intensity Interval Training
Primary: Intrahepatic Triglyceride (IHTG) — 5.26; 8.97 percentage of IHTG — p=0.363
Phase 1 N=240 A Study of Mirikizumab in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab — 14.3; 15.2 micrograms/milliliter (µg/mL)
Phase 3 N=1,208 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
Covid19
Primary: Time to Sustained Recovery in Days — 10; 10 days
N/A N=49 Prevention of Opioid-Induced Hypoxemia
Non-cardiac Surgery
Primary: Time-weighted Average of SpO2 Below a Threshold of 90% — 0.29; 0.11; 0.16; 0.10 % of SpO2 — p=0.120
N/A N=5,696 Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Kenya
Malaria · Febrile Illness
Primary: ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases — 313; 250; 339 Participants
Phase 3 N=444 A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
Lung Diseases, Interstitial
Primary: Number of Patients With Any Adverse Event (AE) Over the Course of the Trial — 441 Participants
Phase 2 N=21 Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria — 0 Participants
N/A N=254 TechStep: Technology-based Stepped Care to Stem Transgender Adolescent Risk Transmission
HIV
Primary: Condomless Intercourse Events — 3.14; 3.17; 3.68 Expected events — p=0.141
N/A N=13,021 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
Pulmonary Arterial Hypertension
Primary: Time to Dementia Onset — 17.9; 18.8; 19.8; 19.9 Incidence rate per 1000 person year
N/A N=294 NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
Acute Rhinosinusitis · Recurrent Acute Rhinosinusitis · Chronic Rhinosinusitis
Primary: Change in the Total Score of the Investigator's Symptomatic Severity Assessment (Day 0, Day 14) — -4.37; -3.56 score on a scale
N/A N=60 Evaluating Two Multifocal Daily Disposable Contact Lenses
Presbyopia
Primary: Comfort Just After Lens Insertion — 9.1; 9.2 score on a scale
N/A N=9,559 Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events
Dyslipidemia · Cardiovascular Diseases · Hypercholesterolemia
Primary: Mean Low Density Lipid-Cholesterol (LDL-C) Levels in High and Very High Risk Cardiovascular Participants — 2.40; 1.99 mmol/L
Phase 1 N=72 A Study of LY3074828 in Healthy Participants
Healthy
Primary: Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3074828 — 14.4; 21.1 microgram per milliliters (μg/mL)